We are the leader in antisense drug development with a broad pipeline of drugs that are applicable to many different disease targets. Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve industry drug discovery productivity.

With our efficient antisense drug discovery platform, we can discover many more drugs than we can develop ourselves. Therefore, we license our drugs to partners prior to late-phase development and commercialization, eliminating the costs associated with a sales and marketing force. This strategy places our drugs in the hands of focused partners who have the expertise and resources to advance our drugs. In addition, we benefit from upfront license fees, milestone payments and royalties as our partners license and develop our drugs. To date, we have generated more than $1.6 billion from the successful execution of this partnership strategy.

Furthermore, as the owner or exclusive licensee of more than 1,600 patents worldwide, we lead the RNA-based therapeutic space. We are continually making improvements to our drug discovery platform and our drugs and expanding our antisense technology to include new opportunities. We look forward to remaining the leader in all aspects of antisense technology advancement.